Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Kondrashova, Olga; Topp, Monique; Nesic, Ksenija; Lieschke, Elizabeth; Ho, Gwo‐Yaw; I. Harrell, Maria; V. Zapparoli, Giada; Hadley, Alison; Holian, Robert; Boehm, Emma; Heong, Valerie; Sanij, Elaine; B. Pearson, Richard; J. Krais, John; Johnson, Neil; McNally, Orla; Ananda, Sumitra; Alsop, Kathryn; J. Hutt, Karla; H. Kaufmann, Scott; Lin, Kevin; C. Harding, Thomas; Traficante, Nadia; Ovarian Cancer Study (AOCS), Australian; Chenevix‐Trench, Georgia; Green, A.; M. Webb, Penelope; M. Gertig, Dorota; Fereday, Sián; Moore, Suzanne; A. Hung, Jillian; Harrap, K.R.; Sadkowsky, T.; Pandeya, Nirmala; Malt, M.; Mellon, A.; Paul Robertson, R.; Vanden Bergh, T.; U. Jones, Milissa; Mackenzie, P.; Maidens, J.; Nattress, K.; Chiew, Yoke-Eng; Stenlake, Annie; C. Sullivan, Harold; M. Alexander, Brian; Ashover, P.; M. Brown, Stephen; Corrish, T.; Green, L.; M. Jackman, L.; Ferguson, Kaltin; Martin, Karla; Martyn, A.; Ranieri, B.; White, J.; Jayde, V.; Mamers, Pam; Bowes, Leanne; Galletta, Laura; A. Giles, Daniel; Hendley, Joy; Schmidt, Thomas; Shirley, H.; Ball, C.; D. Young, Christian; Viduka, S.; Tran, Hang; Bilic, Sanela; Glavinas, Lydia; Brooks, Julia; Stuart‐Harris, R.; Kirsten, Fred; Rutovitz, J; Clingan, P.; Glasgow, Akisha; Proietto, Anthony; Braye, Stephen; Otton, Geoffrey; Shannon, Jenny; Bonaventura, Tony; Stewart, James; Begbie, Stephen; Friedländer, Michael; Bell, Debra; Baron‐Hay, Sally; Ferrier, A.; Gard, G.; Nevell, David; Pavlakis, Nick; Valmadre, Susan; Young, B.; Camaris, C.; Crouch, R.; Edwards, L.; F. Hacker, Neville; E. Marsden, Donald; Robertson, G.M.; Beale, Philip; Beith, Jane; Carter, Jonathan; Dalrymple, C.; Houghton, R.; A. Russell, Prudence; Links, Matthew; J. Grygiel, John; Hill, Jane; H. Brand, Alison; Byth, Karen; Jaworski, Richard; R. Harnett, Paul; Sharma, R.; Wain, Gerard; Ward, B.; Papadimos, D.; Crandon, A.; P. Cummings, Michael; Horwood, K.; Obermair, Andreas; Perrin, Lewis; Wyld, David; Nicklin, James; Davy, Marcus; K. Oehler, Martin; Hall, Cathrine; Dodd, Tom; M. Healy, Timothy; Pittman, Keir; J. Henderson, Deborah; A. Miller, Jessica; Pierdes, J.; Blomfield, Penny; Challis, D.; McIntosh, Rachel; Parker, Alyssa; Brown, Robert; Rome, Robert; G. Allen, David; Grant, Peter; Hyde, Simon; Laurie, R.; Robbie, Melissa; Healy, David; Jobling, Tom; Manolitsas, T.; McNealage, J.; A. W. Rogers, Peter; Susil, B.; Sumithran, E.; Simpson, Ian; Phillips, Kelly‐Anne; Rischin, Danny; B. Fox, Stephen; Johnson, Debi; Lade, Stephen; B. Loughrey, Maurice; O’Callaghan, N.; K. Murray, William; Waring, Paul; Billson, Virginia; Pyman, Jan; Neesham, Deborah; Quinn, Michael; Underhill, Craig; Bell, Rachel; F. Ng, L.; Blum, Robert; Ganju, Vinod; Hammond, Ian; Leung, Yee; J. McCartney, Anthony; Buck, Martin; Haviv, I.; Purdie, D.; C. Whiteman, David; Zeps, Nikolajs; DeFazio, Anna; A. McNeish, Iain; D.L. Bowtell, David; M. Swisher, Elizabeth; Dobrovic, Alexander; J. Wakefield, Matthew; L. Scott, Clare

doi:10.1038/s41467-018-05564-z

Public

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Published in Nature Communications • Sep 24, 2018

Authors:

Olga Kondrashova

Monique Topp

Ksenija Nesic

Abstract

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical mod...

Subject

Cancer research

PARP inhibitor

Methylation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!